EcoDrugPlus

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSXMAG00000020155
Gene Symbol: AGTR1
3 Cross references
198 Possible Orthologues:

Anti-Apoptotic Protein Nr13-Like

Ensembl ID : ENSXMAG00000018227
Gene Symbol: LOC102223228
3 Cross references
128 Possible Orthologues:

Apelin Receptor B-Like

Ensembl ID : ENSXMAG00000012707
Gene Symbol: LOC102225813
3 Cross references
171 Possible Orthologues:

Aph-1 Homolog A, Gamma-Secretase Subunit

Ensembl ID : ENSXMAG00000009804
Gene Symbol: APH1A
3 Cross references
190 Possible Orthologues:

Apurinic/apyrimidinic Endodeoxyribonuclease 1

Ensembl ID : ENSXMAG00000006195
Gene Symbol: APEX1
3 Cross references
212 Possible Orthologues:

Arachidonate 5-Lipoxygenase

Ensembl ID : ENSXMAG00000002683
Gene Symbol: ALOX5
3 Cross references
225 Possible Orthologues:

Arachidonate 5-Lipoxygenase Activating Protein

Ensembl ID : ENSXMAG00000008413
Gene Symbol: ALOX5AP
3 Cross references
200 Possible Orthologues:

Arachidonate 5-Lipoxygenase-Like

Ensembl ID : ENSXMAG00000011887
Gene Symbol: LOC102224924
3 Cross references
200 Possible Orthologues:

Arg8-Vasotocin Receptor-Like

Ensembl ID : ENSXMAG00000028037
Gene Symbol: LOC102224040
4 Cross references
170 Possible Orthologues:

Arginine Vasopressin Receptor 1a

Ensembl ID : ENSXMAG00000023787
Gene Symbol: AVPR1A
3 Cross references
195 Possible Orthologues:

Arginine Vasopressin Receptor 2

Ensembl ID : ENSXMAG00000009554
Gene Symbol: AVPR2
3 Cross references
148 Possible Orthologues:

Arginine Vasopressin Receptor 2

Ensembl ID : ENSXMAG00000010783
Gene Symbol: AVPR2
3 Cross references
178 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).